Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206928 | 0.98 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL315728 | 0.95 | SLC6A3 (0.63) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL334758 | 0.87 | FFAR1 (0.68) | FFAR1TAAR1PKM | |
| SCHEMBL11039334 | 0.87 | NAAA (0.55) | MAPTRXFP1HDAC6FFAR1NAAA | |
| SCHEMBL1197247 | 0.85 | MAPT (0.78) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL19612566 | 0.83 | NAAA (0.55) | MAPTRXFP1SLC6A3HDAC6NAAA | |
| SCHEMBL27914585 | 0.83 | MAPT (0.62) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL28229641 | 0.82 | FFAR1 (0.51) | HDAC3MAPK1ADRA1AHDAC4SLC6A3 | |
| SCHEMBL29197998 | 0.82 | MAPT (0.55) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL25342051 | 0.81 | HDAC3 (0.76) | MAPTRXFP1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | claimed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | claimed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| CN-105233294-A | Phenylalkylcarboxylic acid delivery agent | EMISPHERE TECH INC | 2016-01-13 | — | — | CN | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | claimed |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-02-24 | — | — | US | claimed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | claimed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | disclosed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | MAPT 3128/4885RXFP1 2235/4885HDAC3 487/4885 |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | MAPT 3128/4885RXFP1 2235/4885HDAC3 487/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | MAPT 3128/4885RXFP1 2235/4885HDAC3 487/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MAPT 3620/4885RXFP1 2986/4885HDAC3 2064/4885 |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | MAPT 3128/4885RXFP1 2235/4885HDAC3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.